Lupin stock rises 2% on launch of drug that prevents postpartum hemorrhage
Drug firm Dr Reddy's Laboratories today said it has received establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico.
The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico by the United States Food and Drug Administration (USFDA) was completed with zero observations.
"...we have received an Establishment Inspection Report (EIR) from the USFDA, for the above-referred facility," Dr Reddy's Laboratories said in a filing to the BSE.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Shares of Dr Reddy's Laboratories today closed at Rs 2,112.30 per scrip on BSE, down 0.45 percent from its previous clsoe.